Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy is a research paper published in Pharmaceuticals (2022). On theSindex it has a DataRank of 0.396. It has been cited 13 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.396
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Innovative Project Award from the American Heart Association
Grant: 18IPA34170394
Innovative Project Award from the American Heart Association
Grant: 19PRE34430192
Innovative Project Award from the American Heart Association
Grant: RO1-HL153407
National Institutes of Health
Grant: 5R01HL153407-03
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease
NHLBI NIH HHS
Grant: R01 HL153407
FWCI
0.94
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals